Lung Cancer 2022 May 5;169:13-21. Epub 2022 May 5.
Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université Paris Cité, Team Inflammation, Complement and Cancer, F-75006 Paris, France; Department of Pathology, Hôpitaux Universitaire Paris Centre, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Introduction: SMARCA4/BRG1 loss of expression occurs in 5-10% of non-small cell lung carcinomas (NSCLC). We investigated the pathological, molecular and immune environment characteristics of this deficiency among NSCLC, its impact on overall survival (OS) of resected patients and the sensitivity to anti-PD1 inhibitors in metastatic patients.
Materials And Methods: BRG1 expression was assessed by immunohistochemistry to identify SMARCA4-deficient NSCLC (SD-NSCLC) from the cancer tissue collection of Cochin Hospital (Paris, France). Read More